内容紹介
Clinical Efficacy of Low-Dose CDDP and CPT-11 Therapy as Second- or Third-Line Chemotherapy for Advanced and Recurrent Gastric Cancer
Summary
We retrospectively studied the clinical efficacy and safety of the combination therapy with low-dose cis-diamminedichloroplatinum(CDDP)and irinotecan hydrochloride(CPT-11)as a second- or third-line chemotherapy in 41 patients with advanced and recurrent gastric cancer. Low-dose CDDP(20 mg/m2)and CPT-11(80 mg/m2)were administered intravenously once every 2 or 3 weeks. The patients comprised 31 men and 10 women, with ages ranging from 42 to 81 years(mean, 67.4 years). The overall treatment response rate was 12%, including 5 partial responses but no complete response. The mean survival time was 8 months, and the disease-free survival time was 3.7 months from the start of the regimen. The median number of treatment cycles was 7.1(range, 1.0-26.0). The most common grade 3/4 toxicity was neutropenia(2 cases), followed by dehydration(1 case)and allergy(1 case). Our data suggest that the combination of low-dose CDDP and CPT-11 has mild therapeutic toxicities and may effectively prolong the median survival time in patients with advanced and recurrent gastric cancer.
要旨
進行・再発胃癌に対し,second-line以降で低用量CDDP+CPT-11療法を行った症例についてretrospectiveに検討した。進行・再発胃癌41例を対象とし,CDDP 20 mg/m2,CPT-11 80 mg/m2を各々点滴静注し,2～3週間ごとに外来で施行した。初発進行胃癌の非切除症例17例,術後再発胃癌24例であった。平均年齢は67.4(42～81)歳,男性31例,女性10例。評価病変は,原発巣14例,腹腔内リンパ節27例,肝転移9例,肺転移3例であり(重複あり),second-line 13例,third-line 28例に投与された。CR 0例,PR 5例で奏効率は12.0%,SD 11例であり,病態制御率は40%であった。当レジメン開始からのmedian survival time(MST)は8(2～36.6)か月,disease free survival(DFS)は3.7(0.7～22.4)か月であった。副作用は,grade 4の有害事象は認めず,grade 3はアレルギー1例,脱水1例,好中球減少2例であり,重篤な副作用なく外来で安全に使用することが可能であった。低用量CDDP+CPT-11を用いた外来化学療法は,進行・再発胃癌の今後の治療の選択肢の一つとして考慮される治療であると考えられた。
目次
Summary
We retrospectively studied the clinical efficacy and safety of the combination therapy with low-dose cis-diamminedichloroplatinum(CDDP)and irinotecan hydrochloride(CPT-11)as a second- or third-line chemotherapy in 41 patients with advanced and recurrent gastric cancer. Low-dose CDDP(20 mg/m2)and CPT-11(80 mg/m2)were administered intravenously once every 2 or 3 weeks. The patients comprised 31 men and 10 women, with ages ranging from 42 to 81 years(mean, 67.4 years). The overall treatment response rate was 12%, including 5 partial responses but no complete response. The mean survival time was 8 months, and the disease-free survival time was 3.7 months from the start of the regimen. The median number of treatment cycles was 7.1(range, 1.0-26.0). The most common grade 3/4 toxicity was neutropenia(2 cases), followed by dehydration(1 case)and allergy(1 case). Our data suggest that the combination of low-dose CDDP and CPT-11 has mild therapeutic toxicities and may effectively prolong the median survival time in patients with advanced and recurrent gastric cancer.
要旨
進行・再発胃癌に対し,second-line以降で低用量CDDP+CPT-11療法を行った症例についてretrospectiveに検討した。進行・再発胃癌41例を対象とし,CDDP 20 mg/m2,CPT-11 80 mg/m2を各々点滴静注し,2～3週間ごとに外来で施行した。初発進行胃癌の非切除症例17例,術後再発胃癌24例であった。平均年齢は67.4(42～81)歳,男性31例,女性10例。評価病変は,原発巣14例,腹腔内リンパ節27例,肝転移9例,肺転移3例であり(重複あり),second-line 13例,third-line 28例に投与された。CR 0例,PR 5例で奏効率は12.0%,SD 11例であり,病態制御率は40%であった。当レジメン開始からのmedian survival time(MST)は8(2～36.6)か月,disease free survival(DFS)は3.7(0.7～22.4)か月であった。副作用は,grade 4の有害事象は認めず,grade 3はアレルギー1例,脱水1例,好中球減少2例であり,重篤な副作用なく外来で安全に使用することが可能であった。低用量CDDP+CPT-11を用いた外来化学療法は,進行・再発胃癌の今後の治療の選択肢の一つとして考慮される治療であると考えられた。